Investors with a lot of money to spend have taken a bullish stance on Teva Pharmaceutical Indus TEVA.
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TEVA, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 29 options trades for Teva Pharmaceutical Indus.
This isn't normal.
The overall sentiment of these big-money traders is split between 62% bullish and 27%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $45,185, and 28, calls, for a total amount of $2,568,569.
What's The Price Target?
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $25.0 for Teva Pharmaceutical Indus during the past quarter.
Volume & Open Interest Development
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Teva Pharmaceutical Indus's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Teva Pharmaceutical Indus's significant trades, within a strike price range of $15.0 to $25.0, over the past month.
Teva Pharmaceutical Indus 30-Day Option Volume & Interest Snapshot
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TEVA | CALL | TRADE | BULLISH | 12/20/24 | $1.56 | $1.29 | $1.5 | $18.00 | $1.1M | 92 | 8.5K |
| TEVA | CALL | TRADE | BULLISH | 12/20/24 | $0.85 | $0.82 | $0.85 | $20.00 | $361.2K | 23 | 19.2K |
| TEVA | CALL | SWEEP | BULLISH | 12/20/24 | $0.8 | $0.66 | $0.8 | $20.00 | $119.5K | 23 | 11.5K |
| TEVA | CALL | SWEEP | BEARISH | 06/21/24 | $1.98 | $1.95 | $1.95 | $15.00 | $97.5K | 24.5K | 512 |
| TEVA | CALL | SWEEP | BULLISH | 12/20/24 | $0.82 | $0.8 | $0.82 | $20.00 | $56.4K | 23 | 5.3K |
About Teva Pharmaceutical Indus
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Where Is Teva Pharmaceutical Indus Standing Right Now?
- With a trading volume of 12,615,492, the price of TEVA is up by 0.62%, reaching $16.35.
- Current RSI values indicate that the stock is may be overbought.
- Next earnings report is scheduled for 79 days from now.
Professional Analyst Ratings for Teva Pharmaceutical Indus
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $20.0.
- An analyst from Barclays has decided to maintain their Overweight rating on Teva Pharmaceutical Indus, which currently sits at a price target of $20.
- An analyst from Piper Sandler downgraded its action to Overweight with a price target of $20.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Teva Pharmaceutical Indus options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
